GUTS Logo

Fractyl Health, Inc. Common Stock (GUTS) Stock Forecast & Price Prediction

Live GUTS Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$1.51

-0.10 (-6.21%)

12 Month Price Forecast For GUTS

$1.51
Current Price
$77.44M
Market Cap
3 Ratings
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to GUTS Price Forecasts

+562.3%
To High Target of $10.00
+429.8%
To Median Target of $8.00
+297.4%
To Low Target of $6.00

GUTS Price Momentum

-17.9%
1 Week Change
-20.5%
1 Month Change
-85.5%
1 Year Change
-26.7%
Year-to-Date Change
-85.9%
From 52W High of $10.69
0.0%
From 52W Low of $1.51

๐Ÿค” Considering Fractyl Health (GUTS)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 8, 2025 3:36 AM UTC

GUTS Analyst Ratings & Price Targets

Based on our analysis of 2 Wall Street analysts, GUTS has a consensus that is bullish. The median price target is $8.00, with forecasts ranging from $6.00 to $10.00. Currently, there are 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.

With GUTS currently trading at $1.51, the median price forecast suggests a 429.8% upside. The most optimistic forecast comes from Michael Ulz at Morgan Stanley, projecting a 562.3% upside, while at provides the most conservative target, suggesting a 297.4% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

GUTS Analyst Consensus

3
Buy
0
Hold
0
Sell

GUTS Price Target Range

Low
$6.00
Average
$8.00
High
$10.00
Current: $1.51

Latest GUTS Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for GUTS.

Date Firm Analyst Rating Change Price Target
Feb 3, 2025 Morgan Stanley Michael Ulz Overweight Maintains $10.00
Feb 28, 2024 Evercore ISI Group Umer Raffat Outperform Initiates $0.00
Feb 27, 2024 Morgan Stanley Michael Ulz Overweight Initiates $18.00

Stocks Similar to Fractyl Health, Inc. Common Stock

The following stocks are similar to Fractyl Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Fractyl Health, Inc. Common Stock (GUTS) Financial Data

Fractyl Health, Inc. Common Stock has a market capitalization of $77.44M with a P/E ratio of -0.8x. The company generates $97,000 in trailing twelve-month revenue with a 35.8% profit margin.

Revenue growth is -61.1% quarter-over-quarter, while maintaining an operating margin of -169,957.1% and return on equity of -286.2%.

Valuation Metrics

Market Cap $77.44M
Enterprise Value $55.71M
P/E Ratio -0.8x
PEG Ratio -0.6x
Price/Sales 798.3x

Growth & Margins

Revenue Growth (YoY) -61.1%
Gross Margin +50.0%
Operating Margin -169,957.1%
Net Margin +35.8%
EPS Growth N/A

Financial Health

Cash/Price Ratio +116.6%
Current Ratio 5.6x
Debt/Equity 125.1x
ROE -286.2%
ROA -55.3%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Fractyl Health, Inc. Common Stock logo

Fractyl Health, Inc. Common Stock (GUTS) Company Overview

About Fractyl Health, Inc. Common Stock

What They Do

Develops therapies for type 2 diabetes and obesity.

Business Model

Fractyl Health, Inc. generates revenue by developing innovative therapeutic solutions aimed at treating type 2 diabetes and obesity. Their primary products include the Revita DMR System, an outpatient therapy that addresses duodenal dysfunction, and the Rejuva gene therapy platform, which aims for long-term remission of these metabolic conditions.

Additional Information

Founded in 2010 and headquartered in Burlington, Massachusetts, Fractyl Health, Inc. has evolved from Fractyl Laboratories Inc. and continues to focus on addressing the rising prevalence of metabolic diseases through advanced medical technologies.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

122

CEO

Dr. Harith Rajagopalan M.D., Ph.D.

Country

United States

IPO Year

N/A

Fractyl Health, Inc. Common Stock (GUTS) Latest News & Analysis

GUTS stock latest news image
Quick Summary

Revita focuses on weight maintenance after GLP-1 withdrawal due to demand, with midpoint data expected in Q2 2025 and full enrollment in the REMAIN-1 study by summer 2025.

Why It Matters

Revita's focus on weight maintenance post-GLP-1 withdrawal aligns with market demand, potentially enhancing its competitiveness. Midpoint data in 2025 could impact stock valuation and investor sentiment.

Source: GlobeNewsWire
Market Sentiment: Neutral
GUTS stock latest news image
Quick Summary

Fractyl Health's RJVA-001 successfully targets the pancreas in large animal models, showing effective GLP-1 expression and safety. First-in-human studies are set for 2025.

Why It Matters

Successful preclinical results for RJVA-001 indicate potential for innovative diabetes treatment. Upcoming human studies could drive stock value and market interest in Fractyl Health.

Source: GlobeNewsWire
Market Sentiment: Neutral
GUTS stock latest news image
Quick Summary

Fractyl Health, Inc. (Nasdaq: GUTS) will present new preclinical data from its Rejuva platform at the WCIRDC from December 12-14, 2024, focusing on obesity and Type 2 Diabetes treatments.

Why It Matters

Fractyl Health's presentation of new preclinical data could signal advancements in obesity and diabetes treatments, potentially impacting stock performance and investor sentiment in the healthcare sector.

Source: GlobeNewsWire
Market Sentiment: Neutral
GUTS stock latest news image
Quick Summary

Fractyl Health, Inc. (Nasdaq: GUTS) will have CEO Harith Rajagopalan present at two investor conferences, focusing on obesity and Type 2 Diabetes treatments.

Why It Matters

Fractyl Health's CEO presenting at investor conferences signals potential growth opportunities and increased visibility for the company, which may attract investor interest and affect stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
GUTS stock latest news image
Quick Summary

Fractyl Health, Inc. (NASDAQ:GUTS) will hold its Q3 2024 earnings conference call on November 12, 2024, at 4:30 PM ET, featuring key executives and analysts from major financial institutions.

Why It Matters

Fractyl Health's Q3 earnings call may reveal financial performance and strategic updates, impacting stock valuation and investor sentiment in the healthcare sector.

Source: Seeking Alpha
Market Sentiment: Neutral
GUTS stock latest news image
Quick Summary

Fractyl Health, Inc. (Nasdaq: GUTS) reported rapid enrollment in its REMAIN-1 study, with mid-point data expected in Q2 2025. Topline data from REVITALIZE-1 is anticipated in mid-2025.

Why It Matters

Rapid enrollment in pivotal studies and upcoming data releases signal potential advancements in obesity and T2D treatments, which could impact Fractyl Healthโ€™s stock performance and market position.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About GUTS Stock

What is Fractyl Health, Inc. Common Stock's (GUTS) stock forecast for 2025?

Based on our analysis of 2 Wall Street analysts, Fractyl Health, Inc. Common Stock (GUTS) has a median price target of $8.00. The highest price target is $10.00 and the lowest is $6.00.

Is GUTS stock a good investment in 2025?

According to current analyst ratings, GUTS has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.51. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for GUTS stock?

Wall Street analysts predict GUTS stock could reach $8.00 in the next 12 months. This represents a 429.8% increase from the current price of $1.51. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Fractyl Health, Inc. Common Stock's business model?

Fractyl Health, Inc. generates revenue by developing innovative therapeutic solutions aimed at treating type 2 diabetes and obesity. Their primary products include the Revita DMR System, an outpatient therapy that addresses duodenal dysfunction, and the Rejuva gene therapy platform, which aims for long-term remission of these metabolic conditions.

What is the highest forecasted price for GUTS Fractyl Health, Inc. Common Stock?

The highest price target for GUTS is $10.00 from Michael Ulz at Morgan Stanley, which represents a 562.3% increase from the current price of $1.51.

What is the lowest forecasted price for GUTS Fractyl Health, Inc. Common Stock?

The lowest price target for GUTS is $6.00 from at , which represents a 297.4% increase from the current price of $1.51.

What is the overall GUTS consensus from analysts for Fractyl Health, Inc. Common Stock?

The overall analyst consensus for GUTS is bullish. Out of 2 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.00.

How accurate are GUTS stock price projections?

Stock price projections, including those for Fractyl Health, Inc. Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.